This article is more than 5 years old. Information may no longer be current.
Top five news stories posted in August
Endocrine Today has compiled a list of the top five news reports posted in August. Healio.com/Endocrinology readers were interested in the recall of levothyroxine and liothyronine tablets, role of the microbiome in personalized nutrition, transgender health care, and more.
Thyroid tablets recalled
Drug wholesaler Westminster Pharmaceuticals has issued a voluntarily recall of all unexpired levothyroxine and liothyronine 15-mg, 30-mg, 60-mg, 90-mg and 120-mg tablets, which are packaged in 100-count bottles, according to a company announcement.
Microbiome holds clues to success with personalized nutrition in diabetes
Postprandial glucose responses to specific foods vary from person to person depending on the makeup of his or her gut microbiome, underscoring a need for personalized nutrition to help better manage diabetes, according to a speaker at the annual meeting of the American Association of Diabetes Educators.
Experts push for transgender health priorities in congressional briefing
There is a “durable, biological underpinning” to gender identity that should be considered in any policy determinations that impact transgender people, including antidiscrimination legislation and the coverage of medically necessary treatments for gender incongruence, according to several speakers at an Endocrine Society congressional briefing on transgender health.
New diabetes technology options can ease disease management, but education key
Recent developments and approvals in the diabetes technology space have revolutionized care and glycemic management for type 1 and type 2 diabetes, but patients must be careful to avoid several key mistakes when using insulin pumps and continuous glucose monitoring, according to a speaker at the American Association of Diabetes Educators annual meeting.
InPen system for diabetes receives new regulatory clearances
The FDA has granted clearance for the Android version of the InPen app, making the device the first “smart” pen system for Android users, whereas the EMA has granted a CE mark allowing for availability in international markets, according to two press releases from Companion Medical.